NCT01514487View on ClinicalTrials.gov

Comparison of Three Liraglutide Formulations in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 13, 2005

Primary Completion Date

March 30, 2005

Study Completion Date

March 30, 2005

Conditions
DiabetesHealthy
Interventions
DRUG

liraglutide

One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously

Trial Locations (1)

5000

Novo Nordisk Investigational Site, Adelaide

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01514487 - Comparison of Three Liraglutide Formulations in Healthy Volunteers | Biotech Hunter | Biotech Hunter